头孢他啶-阿维巴坦联合氨曲南与固定复方氨曲南/阿维巴坦对多重耐药铜绿假单胞菌的体外活性比较
该研究对38株临床多重耐药铜绿假单胞菌分离株,采用肉汤微量稀释棋盘法测定头孢他啶-阿维巴坦联合氨曲南与固定复方氨曲南/阿维巴坦的MIC,并计算FIC指数及全基因组测序。结果显示在头孢他啶8 mg/L(EUCAST折点)时,25株分离株对联合方案的MIC低于固定复方;FIC分析显示28例相加、2例协同效应。
要点
- 对多重耐药铜绿假单胞菌,头孢他啶-阿维巴坦联合氨曲南体外敏感性高于固定复方氨曲南/阿维巴坦。
- VIM是最常见碳青霉烯酶(21/38株),VIM-2携带株对联合方案的MIC低于VIM-1携带株。
- FIC分析显示联合方案以相加效应为主(28例),协同效应仅2例。
核心结论
- 体外试验中,头孢他啶-阿维巴坦联合氨曲南对多重耐药铜绿假单胞菌的敏感性高于固定复方氨曲南/阿维巴坦。
研究设计与样本
- 研究纳入38株来自常规诊断的多重耐药铜绿假单胞菌临床分离株。
- 采用肉汤微量稀释棋盘法(三次重复)作为参考方法测定MIC并计算FIC指数,对所有分离株进行全基因组测序。
主要发现
- 在头孢他啶固定浓度8 mg/L(EUCAST折点)时,25株分离株对头孢他啶-阿维巴坦联合氨曲南的MIC低于固定复方氨曲南/阿维巴坦。
- FIC分析显示相加效应28例、协同效应2例。
- 碳青霉烯酶分布:VIM 21/38株、IMP 4/38株、NDM 2/38株。
- 携带VIM-2的分离株对头孢他啶-阿维巴坦联合氨曲南的MIC低于携带VIM-1的分离株。
临床怎么用
- 对于多重耐药铜绿假单胞菌感染,尤其是产VIM酶菌株,可优先考虑头孢他啶-阿维巴坦联合氨曲南方案,但需结合临床情况。
局限性
- 研究仅为体外试验,样本量较小(38株),结论需临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: MDR Pseudomonas aeruginosa is difficult to treat, despite some new beta-lactam/beta-lactamase inhibitors. A combination of ceftazidime-avibactam and aztreonam (CAZ/AVI + AZT) is frequently used to treat Gram-negative bacteria expressing metallo-beta-lactamases. A fixed combination of aztreonam/avibactam was recently licenced for use in Europe, but it remains unknown whether there are differences between both options for use against P. aeruginosa. This study evaluates the comparative in vitro efficacy of the fixed combination aztreonam/avibactam compared to the three antibiotics CAZ/AVI + AZT against clinical MDR P. aeruginosa isolates. METHODS: MICs for aztreonam/avibactam and CAZ/AVI + AZT were determined in 38 MDR P. aeruginosa isolates recovered from routine diagnostics using broth microdilution with checkerboard assays in triplicates as the reference method. Fractional inhibitory concentration (FIC) indices were calculated. Whole-genome sequencing was performed on all isolates. RESULTS: At a fixed ceftazidime concentration of 8 mg/L (EUCAST breakpoint), 25 isolates exhibited lower MICs for CAZ/AVI + AZT compared to aztreonam/avibactam alone in microdilution assays. On FIC analysis, additive and synergistic effects were seen in 28 and 2 cases, respectively. Verona integron-encoded metallo-beta-lactamase (VIM) was the most prevalent carbapenemase (21/38 isolates), followed by Imipenemase (IMP, 4/38) and New Delhi metallo-beta-lactamase (NDM, 2/38). Lower MICs were observed for the combination CAZ/AVI + AZT in isolates carrying VIM-2 as compared to VIM-1. CONCLUSIONS: In vitro testing of CAZ/AVI + AZT revealed increased in vitro susceptibility among MDR P. aeruginosa isolates in comparison to the fixed combination of aztreonam/avibactam.
引用
- Müller SE, Junker S, Rehner J, et al. Comparative in vitro activity of ceftazidime-avibactam plus aztreonam and the fixed combination aztreonam/avibactam against multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother. 2025. PMID: 41077955. doi:10.1093/jac/dkaf376
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。